Skip to Content
Merck
All Photos(3)

Key Documents

View All Documentation

269476

Sigma-Aldrich

N-Acetylprocainamide

≥99%

Sign Into View Organizational & Contract Pricing
All Photos(3)

About This Item

Linear Formula:
4-(CH3CONH)C6H4CONHCH2CH2N(C2H5)2
CAS Number:
32795-44-1
Molecular Weight:
277.36
MDL number:
MFCD00009052
UNSPSC Code:
12352100
PubChem Substance ID:
24856329
NACRES:
NA.22

Assay

≥99%

form

solid

mp

138-140 °C (lit.)

solubility

soluble 1%, clear, colorless to faintly yellow (1N HCl)

SMILES string

CCN(CC)CCNC(=O)c1ccc(NC(C)=O)cc1

InChI

1S/C15H23N3O2/c1-4-18(5-2)11-10-16-15(20)13-6-8-14(9-7-13)17-12(3)19/h6-9H,4-5,10-11H2,1-3H3,(H,16,20)(H,17,19)

InChI key

KEECCEWTUVWFCV-UHFFFAOYSA-N

General description

The relaxant effects of N-acetylprocainamide on bovine tracheal smooth muscle was studied.

Application

N-acetylprocainamide (NAPA) was used as a model drug in the study of establishing a quantitative approach to predict the renal clearances of basic drugs using N-1-methylnicotinamide (NMN).

Pictograms

Exclamation mark
GHS07

Signal Word

Warning

Hazard Statements

H315,H319,H335

Hazard Classifications

Eye Irrit. 2 - Skin Irrit. 2 - STOT SE 3

Target Organs

Respiratory system

Storage Class Code

11 - Combustible Solids

WGK

WGK 3

Flash Point(F)

Not applicable

Flash Point(C)

Not applicable

Personal Protective Equipment

dust mask type N95 (US), Eyeshields, Gloves

Certificates of Analysis (COA)

Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

J E Tisdale et al.
Therapeutic drug monitoring, 18(6), 693-697 (1996-12-01)
The objective of this study was to compare the precision and accuracy of fluorescence polarization immunoassay (FPIA) with high-performance liquid chromatography (HPLC) for measurement of procainamide (PA) and N-acetylprocainamide (NAPA) concentrations in urine. To determine the correlation between FPIA and
Multicenter evaluation of the Abbott AxSYM procainamide and N-acetylprocainamide assays: comparison with Abbott TDx/TDxFLx, Syva EMIT 2000, DuPont ACA, and HPLC methods.
H M Azzazy et al.
Clinical biochemistry, 31(1), 55-58 (1998-04-29)
Y L He et al.
European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences, 13(3), 303-308 (2001-06-01)
The dosage regimen of a drug eliminated predominantly through the kidney need to be adjusted for the patients with renal disease. The objective of the present study was to establish a quantitative approach to precisely predicting the renal clearances of
Application of capillary electrophoresis to the in vitro assessment of drug metabolism.
C M Hill et al.
Biochemical Society transactions, 23(3), 432S-432S (1995-08-01)
M Boucher et al.
Journal of autonomic pharmacology, 18(2), 83-87 (1998-09-08)
1. The cardiac anticholinergic effects of procainamide (1 mg kg(-1) min(-1)) and its N-acetylated metabolite (NAPA) at equimolar dose (1.16 mg kg(-1) min(-1)) were studied using in vivo experimental pharmacological and in vitro radioligand binding studies. 2. Procainamide and NAPA
View All Related Papers

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service